Arbutus Biopharma (ABUS) Tops Q1 EPS by 91c

Arbutus Biopharma (NASDAQ: ABUS) reported Q1 EPS of $0.87, $0.91 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $179.23 million versus the consensus estimate of $400 thousand.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.

You May Also Be Interested In

• Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
• Qualcomm (QCOM) Is Said To Near Deal For Ai Chip Startup Modular - Bloomberg
• Boeing wins $121 million Navy contract for P-8A upgrades